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Background & Aims: Vegetarians and vegans are more vulnerable to vitamin B12 deficiency with 28 
severe risks of megaloblastic anemia, cognitive decline, neuropathy, and depression. An easy and 29 
simple method of supplementation consists of taking one weekly dosage of 2000 µg. However, single 30 
large oral doses of vitamin B12 are poorly absorbed. The present research evaluates the ability of two 31 
different sublingual dosages of vitamin B12 (350 µg/week vs. 2000 µg/week) in improving 32 
cyanocobalamin (vitamin B12) nutritional status in vegans and vegetarians with a marginal deficiency.  33 
Methods: A 12-week randomized, double-blind, controlled, parallel intervention trial was performed. 34 
Forty subjects with marginal vitamin B12 deficiency were enrolled and randomly divided into two 35 
groups: test group Ld (low dose, 350 µg/week) and control group Hd (high dose, 2000 µg/week) 36 
vitamin B12 supplementation. Blood samples were collected at baseline and after 15, 30, 60, and 90 37 
days from the intervention for the determination of vitamin B12, related metabolic markers, and blood 38 
cell counts. 39 
Results: Two-way analysis of variance showed a significant effect of time (P < 0.0001) and of time x 40 
treatment interaction (P = 0.012) on serum concentration of vitamin B12. In particular, 90 days of 41 
supplementation increased the levels of cyanocobalamin (+81.8% in the Ld group and +144.0% in 42 
the Hd group) compared to baseline. A significant increase was observed for the levels of 43 
holotranscobalamin (+64.5% in the Ld group and +165.2% in the Hd group), while a decrease 44 
occurred for the levels of methylmalonic acid (-72.3% in the Ld group and -69.4% in the Hd group), 45 
homocysteine (-56.8% in the Ld group and -53.6% in the Hd group), and folate (-22.8% in the Ld 46 
group and -17.7% in the Hd group) compared to baseline (time effect, P < 0.0001). No difference 47 
was observed between groups (Ld vs. Hd). No effect was detected for the other variables under study. 48 
Conclusions: In our experimental conditions, both supplements were able to restore adequate serum 49 
concentrations of vitamin B12 and to improve the levels of related metabolic blood markers in subjects 50 
with a marginal deficiency. The results support the use of a sublingual dosage of 50 µg/day (350 51 
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µg/week) of cobalamin, instead of 2000 µg/week (provided as a single dose), to reach a state of 52 
nutritional adequacy of vitamin B12 in this target population.  53 
This study was registered at www.isrctn.org as ISRCTN75099618. 54 
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Vitamin B12 (cyanocobalamin) represents an important and essential water-soluble nutrient involved 59 
in the formation of erythrocytes, in the maintenance of the central nervous system, and in cognitive 60 
performance [1]. Cyanocobalamin is present in large amounts in animal products such as meat, organ 61 
meats, shellfish, eggs, milk, and other dairy foods. Plant foods do not contain vitamin B12 unless they 62 
are fortified (e.g., some breakfast cereals); however, the body absorbs animal sources of vitamin B12 63 
much better than plant sources [1,2]. The physiological absorption of vitamin B12 is mediated by the 64 
glycoprotein intrinsic factor (IF). For its absorption, the formation of the IF-B12 complex and the 65 
transport of vitamin B12 across the ileum is required [1,2]. Once absorbed, vitamin B12 is mainly 66 
accumulated in the liver and stored for years before using [1,2].  67 
The recommendations for B12 intakes vary significantly from country to country and individual to 68 
individual [3]. Normally, in healthy individuals with an ordinary omnivorous diet, a daily 69 
consumption of a few micrograms of vitamin B12 is enough to preserve adequate levels of the vitamin 70 
[3,4]. In Italy, the National Reference of Energy and Nutrient Intake Levels (LARN) identified an 71 
average requirement of 2.4 µg a day for adults and up to 2.6 µg and 2.8 µg in pregnancy and lactation, 72 
respectively [4]. A deficiency of vitamin B12 could be the result of gastrointestinal disorders, celiac 73 
disease, Crohn’s disease, and genetic polymorphisms leading to malabsorption of the nutrient [1,2]. 74 
However, this condition is less frequent; elderly and vegetarians are more susceptible to the condition 75 
of vitamin B12 deficiency due to their limited intake of meat products [5,6]. On the contrary, vegans 76 
that exclude animal products from their diet frequently become deficient in vitamin B12. In this regard, 77 
a recent systematic review evaluated the prevalence of vitamin B12 deficiency in individuals adhering 78 
to vegetarian and vegan diets [7]. The authors documented that adherence to a vegan diet was 79 
associated with an increased risk of vitamin B12 deficiency compared to a vegetarian diet [7]. These 80 
findings were in line with the observations reported by other authors [8–11]. 81 
Vitamin B12 deficiency has been associated with several metabolic disorders such as macrocytic 82 
anemia, hyperhomocysteinemia, cardiovascular, cerebrovascular, and neurological disorders [12–83 
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15]. However, despite the high risk of developing vitamin B12 deficiency and related complications, 84 
numerous vegans consider supplementation unnecessary. The deficiency appears after a long period 85 
of depletion (can take years in some), due to the stocks of vitamin present in the liver [16]. Individuals 86 
with serum levels of B12 < 150 pmol/L are considered deficient [16,17], while subjects who have 87 
values between 150 and 221 pmol/L are considered marginally deficient [18,19]. In this specific 88 
situation, the integration of vitamin B12 by the parenteral route is required. However, this approach is 89 
poorly accepted because the results painful and expensive [20] as well as substituted by oral 90 
formulations. However, this is not effective in subjects suffering from vomiting or diarrhea or are not 91 
able to tolerate oral therapies [21]. Moreover, when high doses of vitamin B12 are given orally, only 92 
a small percentage seems to be absorbed. Recently, the administration of vitamin B12 in sublingual 93 
form has been developed [21]. Although sublingual vitamin B12 is often promoted for better 94 
absorption, inconsistent results have been obtained as to the effects of administration of low and high 95 
doses of vitamin B12. 96 
The aim of the present study was to evaluate the ability of two different doses (350 µg/week vs. 2000 97 
µg/week) of sublingual supplements in improving the nutritional status of cyanocobalamin in a group 98 
of vegans and vegetarians with a marginal deficiency. The low dose (Ld) consisted of 7 sublingual 99 
tablets each providing 50 µg/day (350 µg/week) of vitamin B12, while the high dose (Hd) consisted 100 
of 1 sublingual tablet (2000 µg) for the entire week. The latter represents the most common method 101 
of supplementation, even if it is administered by the oral or parenteral route. In this regard, several 102 
studies have shown low absorption following the intake of high doses [1,22]. In addition, this practice 103 
could be less tolerated in some subjects; for example, some authors found adverse effects (e.g., 104 
hyperhidrosis and blurred vision) following supplementation with 1 mg/day of vitamin B12 in 105 
individuals with mild and moderate Alzheimer disease [23]. Our hypothesis is that the sublingual 106 
administrations of low  (350 µg/week) and high (2000 µg/week)  doses of cyanocobalamin are both 107 
able to restore the nutritional adequacy of vitamin B12 within 90 days [24–26] in vegans and 108 
vegetarians affected by a marginal deficiency.  109 
6 
 
2. Materials and Methods 110 
2.1 Subject recruitment  111 
The screening of the participants was performed between March 2015 and July 2016 through 112 
advertisements on bulletin boards, telephone, or e-mail. Subjects were visited for a routine medical 113 
examination by a physician to assess their eligibility to participate in the trial. The eligibility was 114 
assessed by a physician through an accurate examination and by means of a health/medical 115 
questionnaire to exclude subjects with diseases such as diabetes, renal insufficiency, allergies, chronic 116 
constipation, diarrhea, or any other gastrointestinal disorder. Moreover, a small aliquot of blood was 117 
collected to ascertain vitamin B12 nutritional status. Subjects were selected according to the following 118 
inclusion criteria: vegan and vegetarian subjects in a condition of marginal vitamin B12 deficiency (< 119 
220 pmol/L) or full-blown (< 150 pmol/L), non-smokers or light smokers (maximum 5–6 120 
cigarettes/day), and moderate alcohol consumption (up to 14 glasses of wine/beer per week). Subjects 121 
with cardiovascular, coronary, diabetes, hepatic, renal, or gastrointestinal diseases were excluded. 122 
Subjects were not included if using drugs, medications, and/or supplements at least one month before 123 
the beginning of the experiment. Moreover, subjects were excluded if taking vitamin B12 supplements 124 
at least one year before the experiment. The study was performed in accordance with the ethical 125 
standards established in the 2013 Declaration of Helsinki and approved by the Ethics Committee of 126 
the University of Milan (March 4, 2015, ref. 11/15). The study was registered at www.isrctn.org as 127 
ISRCTN75099618. All participants signed an informed consent form. 128 
2.2 Experimental design 129 
A researcher who was not involved in the study and in sample analysis was appointed to allocate 130 
patients to the different treatments according to a randomization list obtained through the center’s 131 
database. The number of participants who were randomly assigned to different study groups, the rate 132 
of patients completing the study, and patients analyzed for the primary outcome are depicted in Figure 133 
1. Forty subjects were enrolled and randomly divided into two groups of 20 subjects each for a 12-134 
week double-blind, randomized, controlled, parallel dietary intervention study. The study was 135 
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performed between May 2015 and October 2016. One group received the supplement at a low dose 136 
(Ld; equivalent to 50 µg/day, 350 µg/week), while the other group (control) received the supplement 137 
at a high dose (Hd; equivalent to 2000 µg/week in a single dose). Vitamin B12 was provided to the 138 
volunteers in one stock at the beginning of the study. Each subject received 13 boxes containing the 139 
doses for a week in a blind condition. All tablets were packaged and numbered (from 1 to 7) in single-140 
dose blisters. Subjects were instructed to follow the sequence of numbers and to swallow one tablet 141 
per day in the morning before breakfast. The Ld group ingested 7 sublingual tablets/week of 142 
cyanocobalamin (50 µg each, equivalent to 350 µg), while the Hd group took only 1 sublingual tablet 143 
of vitamin B12 (2000 µg) and 6 sublingual tablets of placebo. For both groups (Ld and Hd), the tablets 144 
of vitamin B12 consisted of mannitol, maize starch, vegetable stearate magnesium, beet juice, and 145 
sucralose. The placebo tablets matched the shape, size, color, flavor, and the composition of the 146 
vitamin B12 supplements. The sublingual vitamin B12 tablets were obtained from bacteria with a 147 
manufacturing process compatible with the strictly vegan dietary requirements. The crystalline form 148 
of cyanocobalamin was used for the preparation of the tablets. 149 
Subjects were instructed to maintain their dietary and lifestyle habits as declared before enrollment. 150 
Moreover, they were encouraged to abstain from consuming sources of vitamin B12 (e.g., spirulin, 151 
yeast, fortified foods). A 24-hour record of food consumption was kept by each volunteer the day 152 
before blood collection to check compliance with the dietary instructions. Every 2 weeks, subjects 153 
returned the empty blisters (as evidence of the consumption of the tablets) and received the new 154 
supplements. A 3-day food record and a weekly direct interview were also scheduled randomly during 155 
the experimental period to check compliance with the dietary instructions and to assure the 156 
consumption of the tablets. The day of the experiment, after an overnight fast, subjects reported to 157 
the laboratories of the University of Milan. Blood samples were collected at baseline (time 0) and 158 
after 15, 30, 60, and 90 days of intervention. 159 
2.3 Study variables 160 
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The improvement of serum levels of vitamin B12 was considered the primary endpoint. The other 161 
variables under study were as follows: holotranscobalamin, methylmalonic acid, succinic acid, 162 
methionine, homocysteine, vitamin B6, folic acid, and complete blood count. Since the amount of 163 
cobalt provided through the supplement was negligible with respect to the circulating blood levels, 164 
this variable was not evaluated.  165 
2.4 Sampling and analysis of biochemical parameters 166 
Blood was collected in the morning by a phlebotomist. Samples were drawn into evacuated tubes 167 
with or without K2EDTA. Serum was separated within 1 hour, while plasma was separated within 30 168 
minutes (min) after collection by centrifugation (15 min at 2300 X g at 4 °C). Plasma and serum were 169 
aliquoted and stored at -80 °C until analysis. All the samples were analyzed blind. Blood cell count 170 
was evaluated by routine laboratories assessment. 171 
Vitamins B12 levels were measured by a competitive test principle using IF specific for this 172 
vitamin. Vitamin B12 was analyzed by electrochemiluminescence immunoassay (ECLIA) using 173 
Cobas immunoassay analyzers (Roche Diagnostics, North America). Also, the assessment of serum 174 
folate was performed with electrochemiluminescence immunoassay (ECLIA) using Cobas 175 
immunoassay analyzers (Roche Diagnostics, North America). 176 
Holotranscobalamin concentration were determined in serum by immunoenzymatic assay kit 177 
(BIOHIT HealthCare, Helsinki, Finland). Briefly, the microtiter plate wells were coated with a highly 178 
specific monoclonal antibody for BIOHIT Active B12 (holoTC). During the first incubation, holoTC 179 
specifically bound to the surface coated with the antibody. Successively, the conjugate was added for 180 
the binding of holoTC; the wells were then washed to remove unbound components and holoTC was 181 
detected following the incubation with the substrate. Before the analysis, a stop solution was added 182 
and the absorbance was read at 405 nm (mod. F200 Infinite, TECAN Milan, Italy). 183 
Serum vitamin B6 concentrations were evaluated by high performance liquid chromatography 184 
method using the relevant commercial kit (Chromsystems Instruments & Chemicals, Munich, 185 
Germany) [27]. Homocysteine (HCy), methionine (Met), methylmalonic acid (MMA), succinic acid 186 
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(SA), tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl), methanol, and formic acid were 187 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Water was obtained from the Milli-Q apparatus 188 
(Millipore, Milford, MA). The determination of HCy, Met, MMA, and SA was performed according 189 
to Fu et al. [28], with slight modifications. Briefly, 200 µL of heparinized plasma was added to 100 190 
µL of water and 100 µL of TCEP-HCl (0.1 M). The mixture was vortexed for 10 seconds (s), 191 
incubated for 15 min at room temperature, and transferred to an Amicon 10K Da filter. The filter was 192 
centrifuged at 9000 g for 30 min, the filtrate was transferred to a microvial, and 5 µL injected into the 193 
Ultra Performance Liquid Chromatography (UPLC)-high resolution (HR)-mass spectrometers (MS). 194 
The analysis was carried out on an UHPLC model Acquity (Waters) coupled with a High-Resolution 195 
Fourier Transform mass spectrometer (Orbitrap) model Exactive (Thermo Scientific) equipped with 196 
an HESI-II probe for electrospray ionization and a collision cell (HCD). The column was a 1.8 µm 197 
HSS T3 C18 (150 x 2.1 mm, Waters), flow rate was 0.45 mL/min, and the eluents were 0.1% formic 198 
acid in water (A) and acetonitrile (B). The column and sample were kept at 60 °C and 15 °C, 199 
respectively. The UHPLC separation was performed by the following linear elution gradient: 100 % 200 
of A for 5 min, 0 to 100 % B in 1 s, 100 % B for 2 min, from 100 % to 0% B in 1 min, and then 201 
isocratic for 2 min. 202 
For HCy and Met (0–3.2 min), the operative conditions were spray voltage +3.0 kV, sheath 203 
gas flow rate 55, auxiliary gas flow rate 20, capillary temperature 320 °C, capillary +47.5 V, tube 204 
lens +110 V, skimmer +20 V, and heather temperature 120 °C. The acquisition was performed in full-205 
scan mode in the range (m/z)+ 60–180 u.  206 
For MMA and SA (3.2–5 min) the operative conditions were spray voltage -3.0 kV, sheath 207 
gas flow rate 55, auxiliary gas flow rate 20, capillary temperature 320 °C, capillary -35 V, tube lens 208 
-70 V, skimmer -16 V, and heather temperature 120 °C. The acquisition was performed in full-scan 209 
mode in the range (m/z)- 60–130 u and the ions with m/z 91.0038, corresponding to the formic acid 210 
dimer [2M-H]- that was used as the lock mass. The isolation window, automatic gain control target, 211 
injection time, mass resolution, energy, and gas in the collision cell were ±2 ppm, 1 x 106, 100 ms, 212 
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50 K, 20 V, and N2, respectively. The MS data were processed using Xcalibur software (Thermo 213 
Scientific). The peak identity was ascertained, evaluating the accurate mass and the fragments 214 
obtained in the collision cell. Calibration curves were in the range 0.15–14.8, 0.13–33.5, 0.17–42.5, 215 
and 0.25–44 µMolar for HCy, Met, MMA, and SA, respectively. Finally, the wellness parameter was 216 
calculated according to the Fedosov formula [29]: “wellness parameter”: w = log10(holoTCn) + 217 
log10(B12n) − log10(MMAn) − log10(HCyn), where concentrations are normalized (e.g., MMAn = 218 
MMA/MMAn normal).  219 
 220 
2.5 Statistical analysis 221 
Sample size was estimated, based on previous studies, in order to detect significant differences in the 222 
serum vitamin B12 levels [24–26]. Sixteen subjects per group were considered sufficient to 223 
demonstrate at least a 70% improvement in the levels of vitamin B12 after supplementation with a p 224 
value of 0.05 and a power of 80%. The calculation was based on the assumptions that the mean ± 225 
standard deviation (SD) baseline vitamin B12 concentration was 140 ± 40 µmol/L and that the 226 
treatment would increase the levels of cyanocobalamin up to 240 µmol/L. This value represents the 227 
mean found in an Italian blood donor population [4]. 228 
All analyses were performed using STATISTICA software (StatSoft Inc., Tulsa, OK, USA). Results 229 
are expressed as mean ± SD or standard error of the mean (SEM). Data were tested for normality of 230 
distribution by the Shapiro-Wilk test. Variables normally distributed were analyzed by two-way 231 
analysis of variance (ANOVA) considering the treatment (350 µg/week vs. 2000 µg/week) and the 232 
time (0, 15, 30, 60, and 90 days) as dependent variables. Data that were not normally distributed were 233 
logarithmically transformed. Log-transformed data were subjected to analysis by the non-parametric 234 
Friedman test. Differences were considered significant for p < 0.05; the least significant difference 235 
test was applied, as well as post hoc analysis, to show differences between treatments. The level of 236 




3. Results 239 
3.1 Baseline characteristic of the study population 240 
Baseline characteristics of the subjects enrolled in each group are reported in Table 1. Four subjects 241 
(2 for each group) were lost during the follow-up period due to personal reasons. All subjects (n = 242 
36) showed a marginal deficiency of vitamin B12 (< 220 pmol/L) [3]. Regarding the other biomarkers 243 
of cobalamin status: 27 out of 36 subjects had serum levels of MMA above 750 nmol/L (cut-off above 244 
which cobalamin deficiency is diagnosed), while14 out of 36 subjects documented moderate 245 
hyperhomocysteinemia (range 17.6–33.8 μmol/L) with plasma total homocysteine (HCy-pt) value ≥ 246 
15 μmol/L [3]. Moreover, six subjects had folate levels (range 7–9 nmol/L) below 10 nmol/L, 247 
suggesting a folate deficiency [30]. Two subjects showed low vitamin B6 levels (< 21.3 nmol/L) and 248 
one also had low holotranscobalamin levels (< 21 pmol/L) [3]. No abnormalities in blood cell count 249 
were observed. The age, sex, hemoglobin level, platelet and white blood cell counts, mean 250 
corpuscular volume, and serum cobalamin levels were not significantly different between groups 251 
(Table 1). 252 
3.2 Compliance  253 
Subjects were highly motivated to participate in the intervention and confirmed the consumption of 254 
the tablets. The compliance was verified during a weekly direct interview, as previously reported, and 255 
confirmed by returning the empty blisters (100% compliance). Not one participant declared adverse 256 
effects following the supplementation. 257 
3.3 Effect of supplementation on serum levels of total, active, and inactive form of vitamin B12 258 
The serum levels of total vitamin B12, measured at baseline (time 0 day) and after 15, 30, 60, and 90 259 
days from the start of supplementation, are reported in Figure 1. Subjects increased the serum 260 
concentrations of total vitamin B12 to above 240 pmol/L according to our hypothesis. On the whole, 261 
repeated measures of ANOVA did not show a significant effect of treatment, but revealed a 262 
significant effect of time (P = 0.008) and of time × treatment interaction (P = 0.012) for circulating 263 
levels of total vitamin B12 that increased following the treatments. In particular, post-hoc analysis 264 
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showed a significant enhancement after 15 days from the start of the intake of the supplements (+ 265 
51.7% in Ld group vs. +74.2% in Hd group; P < 0.0001). The values increased over time and appeared 266 
significantly different between groups after 30 days until the end of the experimental period (P < 267 
0.01). Figures 2A and 2B show the levels of active (holotranscobalamin, HoloTC) (2A) and inactive 268 
forms (2B) of vitamin B12 measured at baseline and after 15 and 90 days from the start of 269 
supplementation. The analysis at 15 and 90 days was performed based on the prominent absorption 270 
observed in vitamin B12. On the whole, ANOVA did not show a significant effect of treatment and 271 
of time x treatment interaction, but revealed an effect of time (P < 0.0001) for serum circulating levels 272 
of active and inactive vitamin B12 that increased during the treatments.  273 
3.4 Effect of supplementation on serum levels of methylmalonic acid and homocysteine 274 
The serum levels of MMA and HCy were measured at baseline (time 0 day) and after 15, 30, 60, and 275 
90 days from the start of supplementation, are reported in Figures 3A and 3B. ANOVA revealed only 276 
a significant effect of time (P < 0.0001) for serum circulating levels of MMA and HCy that decreased 277 
over time following both treatments.  278 
3.5 Effect of supplementation on serum concentrations of methionine, succinic acid, vitamin B6 279 
and folate, blood cell count, and wellness parameter 280 
The serum levels of Met, SA, vitamin B6, and folate, measured at baseline (time 0 day) and after 15, 281 
30, 60, and 90 days from the start of supplementation, are reported in Table2. ANOVA revealed only 282 
a significant effect of time for serum circulating levels of folate (P < 0.0001), Met (P < 0.0001) and 283 
SA (P < 0.0001). In particular, folate showed a significant decrease over time, while Met and SA has 284 
significant increases.  285 
In Table 2 are reported the values of the wellness parameter measured at baseline (time 0 day) and 286 
after 15 and 90 days from the start of supplementation are reported in Table 2. Since the index derives 287 
from a formula that also takes into consideration the levels of holoTC, this parameter was measured 288 
only at times for which the levels of holoTC were detected. On the whole, repeated measures ANOVA 289 
did not show a significant effect of treatment, but revealed a significant effect of time (P < 0.0001) 290 
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and time × treatment interaction (P = 0.046). In particular, post-hoc analysis documented a significant 291 
improvement over time following the intake of both the supplements, with a difference between 292 
groups only at specific and independent time points. 293 
No effect was documented for serum circulating levels of vitamin B6 and blood cell count (data not 294 
shown).  295 
 296 
4. Discussion 297 
In the present study, we documented that as a little as 350 µg per week of vitamin B12 supplementation 298 
was enough to correct a marginal deficiency of cobalamin and to improve holoTC, MMA, and HCy 299 
(biomarkers of cobalamin status) in a group of vegans and vegetarians. The results obtained support 300 
the use of a sublingual supplement at low doses as an effective and non-invasive method to improve 301 
the cobalamin status in this target population.  302 
It has been reported that the absorption of vitamin B12 from supplements does not depend only on the 303 
dose and frequency of the intake but also on the health status of the subjects. In particular, it is widely 304 
recognized that subjects suffering from gastric or small intestine resections, inflammatory bowel 305 
disease, and other complications related to intestinal absorption may become deficient [31]. 306 
Moreover, the capacity of absorption is strictly dependent on saturable active transport and on the 307 
efficiency of the aspecific route. In this regard, different studies have shown that the absorptive 308 
capacity of vitamin B12 is high when the amount introduced is low. For example, the oral 309 
administration of different doses (1 µg, 10 µg, 50 µg, 500 µg, and 1000 µg) of vitamin B12 are 310 
absorbed with an efficiency of 56%, 16%, 3%, 2%, and 1.3%, respectively [32]. A plethora of studies 311 
investigated the effect of a supplementation on the levels of vitamin B12 and related cardiovascular 312 
markers; however, most of them where performed in the elderly [6,15], those with 313 
hyperhomocysteinemia [33,34], and undernourished children [35,36], while very few are involving 314 
vegetarians and/or vegans. A recent 12-week randomized, placebo-controlled trial performed in 315 
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vegans documented that the use of a vitamin B12-fortified toothpaste (about 100 µg/g depending on 316 
the number of brush sessions) improved serum and plasma concentrations of cobalamin and related 317 
associated markers [37]. Yajnik et al. [26] found that supplementation of vitamin B12 (500 µg/day), 318 
over a 6-week period, significantly increased plasma vitamin B12 concentration (from 125 to 215 319 
pmol/L) in a group of healthy, lacto-vegetarian women. The improvement was observed within the 320 
first 2 weeks of intervention, and the levels maintained stability up to 4 weeks. Sharabi and coworkers 321 
documented similar findings following sublingual and oral administration of 500 µg of cobalamin in 322 
subjects with a deficiency [38]. 323 
In our experimental conditions, supplementation with low and high doses (350 µg/week vs. 2000 324 
µg/week) of cobalamin significantly improved circulating serum levels of vitamin B12, suggesting the 325 
efficiency and efficacy of both supplements in restoring the levels of the vitamin (> 240 pmol/L) [3]. 326 
However, serum levels of vitamin B12 above the cut-off point does not necessarily indicate an 327 
adequate nutritional status. In fact, there is inconsistency among the scientific community regarding 328 
the identification of reference values for cyanocobalamin. Future studies should be performed in order 329 
to identify the cut-offs according to individual variability (i.e., age, sex, etc.) and lifestyle habits (i.e., 330 
vegans, vegetarians). Holotranscobalamin represents the metabolically active form of vitamin B12 331 
that delivers cobalamin to the target cells. Recently, it has been recognized as an early and reliable 332 
marker to discriminate an impaired cobalamin status [39]. However, discrepancies remain about 333 
mode of application and assignment of these cut-off values to diagnose a deficiency. Based on 334 
different populations and criteria, cut-off values from 21 to 45 pmol/L have been proposed as 335 
“suboptimal” [3]. In our study, subjects have shown levels of holoTC within the range of normality. 336 
This is in line with the characteristics of our population that included only individuals with a marginal 337 
cobalamin deficiency. The supplementation with both dosages significantly increased the levels of 338 
holoTC. The improvement was comparable between groups, since only an effect of time, but not of 339 
treatments, was observed. The impact of vitamin B12 supplementation on levels of holoTC has been 340 
evaluated in different studies [40,41]. In a double-blind, placebo-controlled trial, 12 and 24 weeks of 341 
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supplementation with 1000 µg vitamin B12 or 1000 µg vitamin B12 + 400 µg folic acid significantly 342 
increased the levels of cobalamin as well as those of holoTC in elderly subjects [40]. Brito et al., [41] 343 
reported that a single intramuscular injection of 10 mg vitamin B12 (providing 100 mg pyridoxine and 344 
100 mg thiamine) significantly increased, after 4 months, serum vitamin B12 and holotranscobalamin 345 
levels in a group of 27 community-dwelling elderly Chileans.  346 
Other biomarkers of cobalamin status include hematological changes and the metabolites MMA and 347 
HCy. These variables can add valuable information in conjunction with serum holoTC and/or 348 
cobalamin for assessment of B12status. MMA is considered a biomarker of cobalamin function with 349 
regard to its role in the functioning of methylmalonyl-CoA mutase. Serum MMA concentration 350 
increases following an insufficient supply of cobalamin. As previously reported values above 750 351 
nmol/L are used to discriminate a cobalamin deficiency [3].  352 
Plasma HCy is not a specific marker of cobalamin status since it is affected also by dietary factors, 353 
such as folate, choline and betaine, as well as renal insufficiency, lifestyle factors (e.g. alcohol 354 
consumption) and age [42-43]. However, elevated plasma HCy concentration is commonly observed 355 
in subjects with a cobalamin deficiency. In our experimental conditions, most of the subjects showed 356 
baseline levels of MMA and HCy above the cut-off values, while only few subjects showed low levels 357 
of folate. For these reasons, those biomarkers, together with the levels of folate, vitamin B6, Met and 358 
SA, can be considered a valid support for the assessment of the nutritional status of cobalamin in 359 
vegans and vegetarians. In fact, we were able to document a statistically significant decrease in the 360 
levels of MMA and HCy, and a significant increase in the levels of Met and SA. These results were 361 
in line with those obtained by other authors showing a general improvement after cobalamin 362 
supplementation [26,36,40,42]. An improvement in cobalamin nutritional status and a reduction of 363 
HCy and MMA may be also effective in the prevention of cardiovascular risk and neurological 364 
disorders. However, some studies failed to observe a significant modulation in HCy levels. For 365 
example, Sharabi and colleagues [38] did not document a decrease in HCy and MMA following 8 366 
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weeks of intervention with 500 µg/day of sublingual and oral B12 administration in subjects with a 367 
cobalamin deficiency.  368 
As previously reported, there is an interrelationship between vitamin B12 and folate; in particular, 369 
vitamin B12 deficiency can lead to lowered levels of methionine synthetase, which results in folate 370 
deficiency and an increased proportion of the 5-methyl derivative. In our experimental conditions, 371 
we did not quantify the levels of the 5-methyl derivative, but only folate that significantly reduced 372 
following cobalamin supplementation. These results are complex to explain; we may hypothesize that 373 
the improvement in B12 status, also in terms of MMA and HCy, did not require high amounts of folate 374 
to compensate for a cobalamin deficiency. However, we cannot exclude that these fluctuations were 375 
attributed mainly to physiological changes, since the overall vitamin status was maintained within the 376 
range of normality.  377 
A recent and robust biochemical indicator of cyanocobalamin status is the wellness parameter 378 
conceived by Fedosov that takes into consideration the levels of total and active B12 forms and those 379 
of MMA and HCy [29]. The cut-off to discriminate the wellness parameter are as follows: deficiency 380 
w = –1.49; transition w = –0.516; normal w = –0.0, and excellent w = +0.445. In our experimental 381 
conditions, subjects showed a low wellness parameter at baseline (-1.0 for Ld group and -1.3 for Hd 382 
group), documenting a state of marginal deficiency. The supplementation of vitamin B12 significantly 383 
improved the wellness parameter in both the intervention groups.  384 
Finally, we observed no significant effect on blood cell count both at the beginning of the study (see 385 
Table 1) and after the intervention (data not shown). These results are not surprising, since our 386 
subjects were in stage 2–3 of vitamin B12 deficiency and this condition does not affect the levels of 387 
mean corpuscular volume and hemoglobin [43]. 388 
Study limitations 389 
A possible limitation of the study is the lack of a real control group (vegans/vegetarians with a 390 
marginal deficiency who did not take supplements). However, by considering that our subjects were 391 
affected by a marginal vitamin B12 deficiency, the inclusion of a real placebo group 392 
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(vegans/vegetarians without supplements) would not have been possible for ethical reasons. A second 393 
limitation of the study is the lack of a follow-up period post-supplementation in order to verify the 394 
changes in the levels of vitamin B12 and related metabolic markers along the time.  395 
Conclusions 396 
In conclusion, the results obtained have shown that both supplements were able to bring the levels of 397 
vitamin B12 from a marginal deficiency to an adequate nutritional status. In particular, we have 398 
documented an increase of serum concentrations of vitamin B12 and holoTC, and a reduction of MMA 399 
and HCy as markers of vitamin B12 metabolism. These results are in line with the elevation of the 400 
wellness parameter that provides further support for the improvement of the nutritional vitamin B12 401 
status.  402 
Our observations emphasize the importance of supplementation in vegetarians and vegans with a 403 
marginal deficiency, but it should be emphasized that the use of pharmacological doses is unnecessary 404 
in this target group. Moreover, the absence of a consensus on vitamin B12 cut-off values and the high 405 
individual variability make it difficult to identify the real needs for vegans and vegetarians. Further 406 
studies are necessary in order to confirm our findings and verify the effects of sublingual 407 
supplementation in vegans and vegetarians with a severe deficiency and in those affected by 408 
malabsorption and/or impaired metabolism of vitamin B12.  409 
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Figure 1- Study flow-chart showing the process of patient selection and enrolment, allocation to the 554 
two study groups, and rate of patients completing the study. Ld: group treated with low dosage of 555 
vitamin B12 (350 µg/week); Hd: group treated with high dosage of vitamin B12 (2000 µg/week). 556 
 557 







Figure 2- Effect of supplementation on serum circulating levels of total vitamin B12 in the two 563 
intervention groups (Ld vs Hd). The concentrations were measured at baseline (T0) and after 15, 30, 564 
60 and 90 days. 565 
 566 
Figure Legend: 567 
N=18 for each group. 568 
Data are expressed as mean ± SEM. a,b,c,d,eData with different letters are significantly different within 569 
the same treatment (time effect; P<0.05). *,§,#Data with different symbols are significantly different 570 









Figure 3-Effect of supplementation on serum circulating levels of active (A) and inactive (B) form 578 
of vitamin B12 in the two intervention groups (LdvsHd). The concentrations were measured at baseline 579 
(T0) and after 15 and 90 days from the supplementation. Data are expressed as mean ± SEM. 580 
 581 
Figure Legend: 582 
N=18 for each group. 583 
 584 
  585 
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Figure 4-Effect of supplementation on serum circulating levels of MMA (A) and tHcy (B) in the two 586 
intervention groups (Ld vs Hd). The concentrations were measured at baseline (T0) and after 15 and 587 
90 days from the supplementation. 588 
 589 
Figure Legend: 590 
N=18 for each group. 591 
Data are expressed as mean ± SEM. MMA, methylmalonic acid; tHcy, total homocysteine 592 
 593 
